Stock Analysis

Instituto de Diagnóstico Full Year 2023 Earnings: EPS: CL$1.02 (vs CL$92.60 in FY 2022)

SNSE:INDISA
Source: Shutterstock

Instituto de Diagnóstico (SNSE:INDISA) Full Year 2023 Results

Key Financial Results

  • Revenue: CL$218.9b (up 14% from FY 2022).
  • Net income: CL$144.3m (down 99% from FY 2022).
  • Profit margin: 0.1% (down from 6.8% in FY 2022). The decrease in margin was driven by higher expenses.
  • EPS: CL$1.02 (down from CL$92.60 in FY 2022).
earnings-and-revenue-history
SNSE:INDISA Earnings and Revenue History March 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Instituto de Diagnóstico's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Instituto de Diagnóstico (2 can't be ignored!) that you need to be mindful of.

Valuation is complex, but we're helping make it simple.

Find out whether Instituto de Diagnóstico is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.